OVATION Pharmaceuticals, Inc. announced today that the U.S. FDA has accepted for review the Biologics License Application (BLA) for ATryn (antithrombin alfa). OVATION acquired the exclusive U.S. license to ATryn in August from GTC Biotherapeutics.........
The details can be read here.
No comments:
Post a Comment